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Abstract 
In Japan, cetuximab with concurrent radiotherapy (BRT) for squamous cell carcinoma of 
head and neck (SCCHN) was approved in December 2012. We herein report our initial experience of 
BRT with special emphasis on acute toxicities of this combination therapy. Thirty-one non-metastatic 
SCCHN patients who underwent BRT using cetuximab between July, 2013 and June, 2014 were 
retrospectively evaluated. All patients received cetuximab with a loading dose of 400 mg/m2 one 
week before the start of radiotherapy, followed by 250 mg/m2 per week during radiotherapy. The 
median cycle of cetuximab was 7 cycles and median dose of radiotherapy was 70 Gy. Twenty-five 
(80.6%) patients accomplished planned radiotherapy and 6 cycles or more cetuximab administration. 
Six patients (19.4%) discontinued cetuximab. Grade 3 dermatitis, mucositis, and infusion reaction 
occurred in 19.4%, 48.3%, and 3.2%, respectively. One patient experienced grade 3 gastro-intestinal 
bleeding caused by diverticular hemorrhage during BRT. Grade3 drug-induced pneumonitis occurred 
in two patients. The response rate was 74%, including 55% with a complete response. BRT using 
cetuximab for Japanese patients with SCCHN was feasible as an alternative for cisplatin-based 
concurrent chemoradiation, although longer follow-up was necessary to evaluate late toxicities. 
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INTRODUCTION 
Numbers of patients with squamous cell carcinoma of the head and neck cancer (SCCHN) 
has been increased in Japan, and more than 20,000 patients suffered from oral/pharyngeal or laryngeal 
cancer, accounting for 2.7% of all cancer cases [1,2]. Cisplatin based concurrent chemoradiotherapy is 
one of the standard treatment for locoregionally advanced SCCHN [3,4]. However, in the clinical 
practice, patients with poor medical condition sometimes fail to receive full dose of chemotherapy 
during definitive radiotherapy for SCCHN, where treatment volume includes wide range of 
oral/pharyngeal mucosa. Cetuximab, epidermal growth factor receptor (EGFR)-targeting monoclonal 
antibody, has shown the antitumor activity for SCCHN expressing EGFR [5]. Because targeted 
therapy agents such as cetuximab are directed selectively at specific target, combination of these 
agents and radiotherapy is considered to be more tolerated than conventional chemotherapy. Bonner et 
al. reported that bioradiatherapy (BRT) had significant survival advantage over radiotherapy alone for 
the treatment of SCCHN [6, 7]. In addition, there was no significant difference in acute radiation 
dermatitis between with and without cetuximab groups in that study. Based on these results, in Japan, 
cetuximab for SCCHN was approved by the Ministry of Health, Labour and Welfare in December 
2012. We herein report our initial experience of treating SCCHN with definitive radiation therapy and 
concurrent cetuximab with special emphasis on acute toxicities of this combination therapy. 
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MATERIALS AND METHODS 
Patients 
Between July 2013 and June 2014, 31 non-metastatic SCCHN patients underwent BRT 
using cetuximab in our hospital. Patient characteristics were shown in Table 1. The median age was 72 
years (range; 52 – 83 years). The primary tumor site was hypopharynx in 14, oropharynx in 12, larynx 
in four, and maxillary sinus in one. The Eastern Cooperative Oncology Group (ECOG) performance 
status (PS) was 0 in 17, 1 in 12, and 2 in two. Reasons for not receiving standard cisplatin-based 
concurrent chemoradiation were patient’s age higher than or equal to 75 years in 10, cardiovascular 
disease in four, cerebral vascular disease in two, diabetes mellitus in two, hepatitis in one, 
schizophrenia in one, poor medical status due to history of preceding other cancer treatment in four, 
and attending physician’s discretion in seven.  All patients had a histologically confirmed diagnosis 
of SCCHN. The stage of the tumor was determined on the basis of physical examination, 
pharyngo-laryngoscopy and radiographic methods such as computed tomography (CT) or magnetic 
resonance imaging (MRI), and PET/CT if available. According to the UICC stage system (7th ed. 
2009), one was stage I, two were stage II, four were stage III, and remaining 24 (77.4%) were stage IV. 
This retrospective study was approved by the Institutional Review Board of our hospital and 
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performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and 
its later amendments. Written informed consent was obtained from all patients. 
 
Radiotherapy planning and techniques 
All patients were consecutively treated with same high-energy linear accelerator (Clinac iX, 
Varian). The CT-based three-dimensional treatment planning was performed for all. Targets and 
organs at risk were contoured on the planning CT. The gross tumor volume (GTV) included the gross 
extent of the primary disease and involved lymph node metastases, taking clinical and radiological 
findings into account; the clinical target volume (CTV) was defined by adding 10-15mm margin to the 
GTV. In addition, nodal CTV was set by considering lymph node level depending on the primary 
tumor and involved nodal sites. The planning target volume (PTV) was defined with additional 
circumferential 5-10 mm margin to accommodate the daily patient set-up uncertainty. Tumor and 
critical structure delineation were performed on co-registrated diagnostic MRI images if necessary. 
Patients received once-daily radiotherapy that consisted of 2.0 Gy per fraction, five fractions per week, 
to the prescribed total dose of 70 Gy in 7 weeks. The three-dimensional conformal radiotherapy 
(3DCRT) or intensity-modulated radiation therapy (IMRT) was performed. When target volume did 
not contain large volume of major salivary grand or oral-pharyngeal mucosa, 3DCRT was selected 
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(n=26), otherwise IMRT was applied (n=5), as an initial treatment. In case of IMRT, PTV was 
modified by subtracting 3 to 5 mm from the skin surface. After administration of 40 to 50 Gy, target 
volumes were shrunken to cover the primary tumor and gross nodal disease with generous margins.  
In 11 cases initially treated with 3DCRT to the dose of 40 to 46 Gy, radiotherapy technique was 
changed to IMRT for the remaining treatment course because it seemed difficult to deliver adequate 
dose to the target with safely sparing the spinal cord above this dose level. 
 
Schedule of cetuximab 
All patients were treated according to the Bonner Protocol. [6,7] An intravenous loading 
dose of cetuximab 400 mg/m2 was administered in a week before beginning radiotherapy, followed by 
250 mg/m2 per week during radiotherapy. Cetuximab was discontinued for grade 3 or worse 
hypersensitivity. Premedication included intravenous chlorpheniramine and dexamethasone. Patients 
received oral prophylaxis of acne with clarithromycin (400mg/day). Oral magnesium supplements 
were titrated up to 3 tablets of magnesium oxide (250 mg per tablet) given 3 times daily. 
 
Toxicity and response assessment 
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Patients were examined every week by both radiation oncologists and head and neck 
surgeons. Adverse events were graded based on the National Cancer Institute Common Terminology 
Criteria for Adverse Events, version 4.0 (CTCAEv4). Patients who developed greater than grade 2 
dermatitis were intensively managed by our skin care team. Responses of BRT were assessed by 
physical examination, endoscopy, and CT and/or MRI, and classified according to the Response 
Evaluation Criteria for Solid Tumors (RECIST) version 1.1.  
 
Statistical analysis 
In this study, effects of patient factors or radiotherapy parameters on the development of 
grade 3 dermatitis/mucositis were examined. All statistical analyses were done with StatMate V 
(ATMS Co., Ltd., Tokyo, Japan).  Fisher's exact test was used to compare categorical variables, such 
as age, sex, and primary tumor subsites.   
 
RESULTS 
The median follow-up time was 12 months (2-18 months). Table 2 shows the number of 
cetuximab cycles and doses of radiotherapy. The median cycle of cetuximab was 7 cycles and median 
dose of radiotherapy was 70 Gy. Six patients (19.4%) discontinued cetuximab administration. Only 
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four patients received less than 6 cycles of cetuximab. One patient who developed infective 
endocarditis at 36 Gy received only 4 cycles of cetuximab and was not able to complete planned BRT 
thereafter. Of three patients who received 5 cycles of cetuximab, drug-induced pneumonitis and 
hypersensitivity reaction developed each in one. Another one patient who received 5 cycles of 
cetuximab due to severe dermatitis accomplished radiotherapy. Of four patients who received 6 cycles 
of cetuximab, two changed their treatment strategy at BRT of 56Gy and 66Gy, respectively. In total, 
25 (80.6%) patients had accomplished planned 70 Gy of radiotherapy and 6 cycles or more cetuximab 
administration.  
Treatment-related acute toxicity profiles are shown in Table 3. There was no grade 4 or 
worse acute adverse event. Grade 3 dermatitis, mucositis, and infusion reaction occurred in 6 patients 
(19.4%), 15 patients (48.4%) and one patient (3.2%), respectively. Typical cases of grade3 
dermatitis/mucositis are shown in Fig1, 2. Confluent painful mucositis with moderate edema 
dominated the pharyngeal wall, epiglottis, pahryngo-epiglottic fold, and tongue base of the patient. 
One month after BRT, still thick yellowish mucositis remains in the pharyngeal wall, epiglottis, and 
pahryngo-epiglottic fold with increased edema of the epiglottis. Confluent moist desquamation with 
white-yellowish surface which indicated superficial infection developed in both side of neck down to 
supraclavicular area corresponding to radiotherapy field. It took almost one month after completion of 
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BRT to recover skin/mucosa reaction. Grade 2 and 3 acne-like skin rash occurred in seven and two 
patients, respectively, and the locations of rash were the face, irradiated neck, the chest wall and the 
back. Grade3 drug-induced pneumonitis occurred in two patients with a smoking history, one patient 
experienced at the fifth weeks during BRT and the other experienced two weeks after the completion 
of the radiation therapy (Fig. 3). For both patients, management of pneumonitis required steroid pulse 
therapy. The latter patient also experienced grade 3 gastro-intestinal (GI) bleeding caused by 
diverticular hemorrhage during BRT. That patient required endoscopic hemostasis and blood infusion 
for anemia. Grade3 hypomagnesemia occurred in 2 patients, despite initial attempts for preventing 
hypomagnesemia using oral magnesium intake. 
Eighteen patients required active nutritional support, nasogastric tube feeding in 15 patients 
and intravenous hyperlimentation in three. The median time of beginning tube feeding was 3.5 weeks 
after the start of BRT. Fifteen patients with grade 3 mucositis required hospitalization during BRT. In 
total, twenty-nine patients admitted to hospital due to dysphagia or mucositis. The median time of 
developing mucositis after the start of radiotherapy was 19 days, and the median time required for 
healing of mucositis after completion of BRT was 31days. 
Effects of radiotherapy technique or patient factor on the development of grade 3 dermatitis 
or mucositis were evaluated. Five of 26 patients treated initially with 3DCRT developed grade 3 
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dermatitis, whereas one patient treated with IMRT experienced grade 3 dermatitis. Grade3 mucositis 
was observed in 14 patients and one patient, respectively for those treated with 3DCRT and IMRT. 
However, there was no statistically significant difference between the two groups concerning the 
development of grade 3 skin/mucosal toxicities probably due to the small number of patients in IMRT 
group. Among 11 patients who initially underwent 3DCRT and changed to IMRT for the later 
treatment course, one and eight patients developed grade 3 dermatitis and mucositis, respectively. 
There was also no significant difference in age, sex and primary tumor subsite between patients with 
and without grade 3 skin/mucosal toxicities. 
Complete response was obtained in 17 and partial response in six, resulting the response 
rate of 74.2%. During the follow-up period, seven patients relapsed in radiotherapy field. At the time 
of data analysis, two patients developed multiple lung metastases and died of respiratory failure. 
 
DISCUSSSION 
Results of the present study show that grades 3 radiation dermatitis and mucositis occurs in 
approximately 20% and 52% of HNSCC patients treated with BRT. Although some investigators had 
reported much higher G3/4 dermatitis in patients receiving BRT [8–11], the incidence rates in the 
present study are quite similar as compared with those originally reported by Bonner et al. [6]. Most 
patients could complete BRT and only six patients received less than 6 cycles of cetuximab. Thus, 
 10 
 
concerning the compliance of cetuximab and radiotherapy, our findings suggest that BRT for Japanese 
patients with SCCHN is, in general, tolerable and acceptable treatment. The adverse event profile in 
this study was mostly in line with that expected with the concomitant administration of cetuximab and 
radiotherapy. The overall incidence of grade 3 or 4 adverse event in this study was similar to that seen 
in the cetuximab plus radiotherapy arm of the Bonner trial. In three patients, however, unexpected 
grade 3 toxicities of GI bleeding or interstitial pneumonitis were observed. Murakami et al. reported 
four patients out of 15 who received BRT experienced GI bleeding which was not yet reported from 
foreign investigators. They reported that most patients with GI bleeding also experienced severe 
dermatitis and mucositis requiring total parenteral nutrition, suggesting that these patients might have 
had susceptibility for cetuximab not only in their gastrointestinal tract, but also skin epithelium and 
pharyngeal mucosa [11]. In the present study, one experienced diverticular hemorrhage requiring 
endoscopic hemostasis and blood transfusion for anemia during BRT. Although it is still unknown 
whether GI bleeding was due to racial characteristics of Asian patients or not, physicians in Japan 
should pay special attention to occurrence of GI bleeding during BRT. Pneumonitis requiring steroid 
pulse therapy is another concern. Drug-induced lung injury (DLI) requiring steroid pulse therapy was 
occurred in two patients with a history of smoking in this study. Severe DLI occurring during 
treatment sometimes induces respiratory failure, and can be fatal. Satoh et al. indicated that older age 
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and prior interstitial lung disease were the primary factors associated with the onset of DLI. [12] They 
recommended that in case of suspected or confirmed DLI, the cetuximab-based chemotherapy should 
be discontinued immediately, and adequate approaches including consultation with a pulmonologist 
and steroid pulse therapy, should be implemented as soon as possible. Because not a small numbers of 
patients receiving Gefitinib for non-small cell lung cancer succumbed to death due to interstitial 
pneumonitis in Japan as compared to in the rest of the world, this type of adverse event should closely 
monitored when using EGRF inhibitor for cancer treatment in Japan [12,13,14]. 
Management of adverse events required rigorous patients care in this study. Although the 
overall incidence of grade 3 adverse events was similar to those reported by others [6,7,15–18], most 
patients required unexpected hospitalization and nutritional support. It was considered that relatively 
poor patient’s background, as compared with those who underwent standard cisplatin-based 
chemoradiation, was responsible for deterioration of general condition during BRT. We examined the 
effect of radiotherapy technique or patient factor on the development of dermatitis or mucositis. 
However, there was no significant association between development of grade 3 dermatitis/mucositis 
and patient’s age, sex, the primary tumor subsites and radiation technique. It was reported that higher 
radiation dose to the skin was significantly correlated with the development of grade 3 dermatitis in 
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the cetuximab cohort [9,19]. Most our patients have received prescribed total dose of radiotherapy, and 
it was difficult for us to access the effect of skin dose on the development of grade 3 dermatitis. 
Concerning the treatment for dermatitis and mucositis, no definitive consensus is still 
established. [20] Bernier et al. devised the grading and a therapeutic method of dermatitis by 
cetuximab [21,22]. They indicated that the glucocorticosteroid creams or ointments could be helpful to 
treat xerosis, which reduce water loss from the skin. However there is no consensus regarding the 
efficacy of glucocorticosteroid in the management of radiation dermatitis induced by cetuximab. Some 
authors suggest that topical glucocorticoids may potentiate the cutaneous toxicity of EGRF inhibitors 
[23]. Gutiérrez et al., on the other hand, described in their systematic review that the use of 
corticosteroids is not contra-indicated in the presence of radiation dermatitis if the overall treatment 
time of any corticosteroids-containing treatment is limited to 1-2 weeks. [24] In contrast, we have used 
steroid cream for a long term, because the versatility of steroid was wide and the steroid contributed to 
the improvement of inflammation. Topical treatment for wet desquamation was the mixture of 
Dimethyl isopropylazulene and Gentamicin sulfate covered with the silicon gauzes. Dry desquamation 
and acne-like skin rashes were treated with topical corticosteroid. In addition, it is important to keep 
the skin clean, moist and anti-inflammatory. To keep these conditions, it seems that the continuous use 
of the steroid is necessary at this time. In the future, it is expected that more effective topical medicine 
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than steroid cream can be available in the clinical practice. As for acne-like rash, patients were treated 
with oral antibiotics, and no patients experienced skin infection in this study. 
The limitations of this retrospective study include selection bias and intervention bias. 
Number of patient was too small to perform meaningful statistical analyses. However, this study 
showed that BRT was generally tolerable for SCCHN patients in Japan. 
 
CONCLUSION 
Concurrent radiotherapy with cetuximab was generally well tolerated. BRT was acceptable 
for the patients with SCCHN who had either older age or comorbidities. Response rate was 74.2%. 
Despite grade3 dermatitis or mucositis experienced in considerable numbers of patients, most could 
have received planned dose of radiotherapy. It was considered that the employment of cetuximb for 
Japanese patients with SCCHN was feasible as an alternative for cisplatin-based concurrent 
chemoradiation, although longer follow-up was necessary to evaluate late toxicities. 
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A    B     C 
 
Fig. 1 
A) Hypopharyngeal tumor with pool of saliva and normal mucosa before the start of bioradiotherapy. 
B) Decrease in the tumor bulk and development of grade 3 mucositis during bioradiotherapy.  
C) Confluent mucositis one month after the end of bioradiotherapy. 
A          B 
 
Fig. 2 
A) Grade3 dermatitis with contact bleeding occurred at one week after bioradiotherapy.  
B) Resolution of dermatitis at 4 weeks after bioradiotherapy.  
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Fig. 3  
Drug-induced lung injury (DLI) developed at 2 weeks after the end of bioradiotherapy in patient with 
oropharynx cancer. He also had diverticular hemorrhage at the second week of bioradiotherapy.  
A) Bilateral interstitial infiltration and consolidation can be seen on chest X-ray image.  
B) Chest computed tomography scan shows widespread ground-glass opacity with 
peribroncho-vascular thickness which was predominant in bilateral upper lung. 
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Table 1. Patient and tumor characteristics 
 
Median age, years (range)   72 (52-83) 
Gender 
 Male    29 
 Female    2 
ECOG PS 
 0    17 
 1    12 
 2    2 
Comorbidities* 
 The elderly patients (≥ 75 y/o)     10 
        Cardiovascular disease   4 
       Cerebral vascular disease  2 
Diabetes Mellitus   2 
Hepatitis        1 
 Schizophrenia   1 
Poor medical status            4    
 Discretion of physician    7 
 
Primary tumor site 
 Hypopharynx   14 
 Oropharynx   12 
 Larynx    4 
 Maxillary sinus   1 
T-stage 
T1            3 
      T2       9 
      T3                     8 
 T4a    10 
      T4b    1 
N-stage 
 N0    10 
 N2b    13 
 22 
 
        N2c    7 
 N3    1 
UICC stage 
 I    1 
 II    2 
 III    4 
 IVA    23 
 IVB    1 
 
 
*: reason not receiving standard cisplatin-based chemoradiation 
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Table 2.  Cycles of cetuximab administration and dose of radiotherapy 
 
Cetuximab cycles 
 4     1 
5     3 
 6     4 
 7     13 
 8     7 
 9     2 
 10     1 
Dose of radiotherapy 
 <60 Gy     3 
 60-69 Gy     2 
 70 Gy     26* 
 
*including one patient who discontinued cetuximab administration due to severe dermatitis 
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Table 3.  Treatment-related acute toxicity 
 
    Grade 2 (%)  Grade 3 (%) 
 
Dermatitis    19 (61.3)   6 (19.4) 
Mucositis    15 (48.4)   15 (48.4) 
Xerostomia   10 (32.3)   0 (0) 
Acune-like skin rashes  7 (22.6)   2 (6.5) 
Infusion reaction   0 (0)   1 (3.2) 
Hypomagnesemia   1 (3.2)   2 (6.5) 
Drug-induced lung injury  0 (0)   2 (6.5) 
GI bleeding   0 (0)   1 (3.2) 
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